Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Zybrestat combretastatin A4P: Interim Phase Ib data

Interim data from 6 patients in an open-label, dose-escalation Phase

Read the full 107 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE